Navigation Links
Doctor-aided suicide: No slippery slope
Date:9/26/2007

2005 that it was concerned with the risks that legalization [of physician-assisted suicide] posed to vulnerable populations, including poor persons, patients with dementia, disabled persons, those from minority groups that have experienced discrimination, those confronting costly chronic illnesses, or very young children.

Tracking Down Data on Physician-Assisted Deaths

Battin and her colleagues wanted to look at what actually has happened in two places where it is legal for doctors to help patients end their lives:

  • Oregon is the only U.S. state where physician-assisted dying is legal. The Oregon Death with Dignity Act was passed by voters in 1994 and 1997, survived numerous challenges and was upheld by the U.S. Supreme Court in 2006. The law allows doctors to prescribe lethal medications to patients who have been diagnosed by two physicians as having a terminal illness and less than six months to live.

    In the first nine years after the law took effect, 456 patients received lethal prescriptions and 292 of those actually used the drugs to kill themselves. That is 0.15 percent of all deaths in Oregon during the same period.

  • The Netherlands has a 2002 law that allows doctors to prescribe medication for suicide or perform voluntary active euthanasia, in which the physician rather than the patient administers life-ending medication. Dutch law does not require terminal illness, but you have to be facing intolerable suffering, Battin says. Physician-assisted suicide and voluntary active euthanasia have been openly tolerated in the Netherlands since the 1980s under guidelines from the courts and medical groups.

    Of 136,000 deaths annually in the Netherlands, about 1.7 percent are by voluntary active euthanasia, 0.1 percent by physician-assisted suicide and 0.4 percent are extralegal because they involve patients with no current explicit request to die, but who either made one before bec
    '/>"/>


Contact: Lee Siegel
leesiegel@ucomm.utah.edu
801-581-8993
University of Utah
Source:Eurekalert

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...cal trials presented by Calpis Co., Ltd. at the Am...Annual Scientific Meeting and Exposition (ASH 2008...y supplement AmealPeptide reduces blood pressure i...D (Achieve Hypertension Efficacy with AmealPeptide...tive, Two-phase Randomized, Open-Label, Blinded En...
(Date:5/16/2008)... -- Superior launch strategies,allow best-in-class...,crowded markets. To secure "share of voice" for a...ptake strategies to support business needs and,ens...l companies achieve,attention in the market during...., "Best Practices for Winning Product Launch Suc...
(Date:5/16/2008)...d Information Technology That, Optimizes Cardiolo...ases Efficiency, SE...ced clinical and,information technology (IT) for t...www.siemens.com/healthcare ) will demonstrate the ...iology and cardiology workflow and image,processin...
(Date:5/16/2008)...PRNewswire-FirstCall/ -- BMP,Sunstone Corporation ...and,distribution pharmaceutical companies, today a...owing conferences:, (1) The Roth Annual China D...David Gao, Chief Executive Officer of the Company,... 2008, at 4:40 pm local time at the Regent Ho...
Breaking Medicine News(10 mins):Health News:Calpis' AmealPeptide lowers blood pressure in 2 placebo-controlled trials 2Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 2Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 3Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 4Health News:Siemens Healthcare Showcases Its Portfolio of Image Management Solutions at SIIM 2008 5Health News:BMP Sunstone Announces Participation in May Investor Conferences 2
...ts may be beneficial in preventing severe long-ter...resently there exists no effective treatment for t...isability is most likely to appear. The Children...ing in the Journal of Neuroscience, and conducted...
...C, Wednesday to demand more funds for cancer resea...traveled to the rally in Washington.// She said, "...hes so many people, but on the other hand, it's em...eople willing to volunteer, give their time and th...
...nesday reported having updated the warning label o...sers about the higher risk of blood clots from it....missioned study revealed that drug users faced two... lungs compared to women taking traditional birth-...
...rpose of a sunscreen lotion as well as offers prot...searchers//, well on the threshold of a discovery;...athway that will prevent the fair skin people from...ainst cancer. Study's lead author, Dr. David E. F...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
(Date:5/16/2008)...Newswire-FirstCall/ -- Pulmo BioTech Inc. (OTC,Bul... methodology and,purpose of its Phase I Human Tria... for the diagnosis of Pulmonary Embolism and Pulmo...by the Pulmo BioTech subsidiary,PulmoScience Inc....the Use,of PulmoBind for Molecular Imaging of the ...
(Date:5/16/2008)...ay 16 /- Data from three studies,eval...moglobin (Hb) levels,and the rate of blood transfu...ons on reimbursement for erythropoiesis-stimulatin...,s blood supply, will be presented at the,American...g later this,month. The meeting will take place in...
(Date:5/16/2008)...bles First-Ever PEGylation of a Small Molecule wit...ity, SAN CARLOS, Calif., May 16 /PRNewswire-First...unced initial results today from a Phase 1,study o...significant,anti-tumor activity in patients with r...s that Nektar,s small molecule PEGylation technolo...
(Date:5/16/2008)...Dual Mechanism May Offer Novel Approach to Blood ...ORLEANS, May 16 /- Pharmaco... and development of novel small,molecule therapeut...lass,Dual Acting Receptor Antagonist (DARA), showe...ons in a Phase 2a study in patients with mild to,m...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Alticors 2007 Global Sales Top 247 Billion 11136 1Alticors 2007 Global Sales Top 247 Billion 11136 2Alticors 2007 Global Sales Top 247 Billion 11136 3Alticors 2007 Global Sales Top 247 Billion 11136 4Alticors 2007 Global Sales Top 247 Billion 11136 5Alticors 2007 Global Sales Top 247 Billion 11136 6Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 1Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 2Shengtai Pharmaceutical Inc Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008 3072 3AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 1AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 2AstraZeneca Gives 241 5 million to Support North Carolina Worksite Wellness Project 11133 3HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 1HMS Holdings Corp Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 11130 2
...SS WIRE)--Jul 9, 2007 - ZIOPHARM,Oncology, Inc. (N...from an ongoing phase II trial of ZIO-201 (isophos... patients was presented at the,European Society of...07 in Lugano, Switzerland. The abstract entitled, ...coma," was presented by,Rashmi Chugh, MD, a Princi...
...--Jul 9, 2007 - TransPharma Medical,Ltd., a specia...ent,and commercialization of drug products utilizi...technology, announced today,promising results of i...y and pharmacokinetic profile of its ViaDerm-hPTH ... A seven day, repeated dose application, parallel ...
Other Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3
We have water perfused manometric catheters for esophageal, anorectal and vector volume diagnostic tests. All Medtronic Water Perfused Catheters are made using clear, medical grade PVC tubing. For pr
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator.
...dtronic offers a family of single-use products to ...or you. This single-use catheter reduces cross-con...e risk of infection and, because cleaning is elimi...have water perfused manometric catheters for esoph...
Medicine Products: